BRPI0809913A2 - Derivados de 2,6-naftiridina como moduladores da proteína quinase - Google Patents
Derivados de 2,6-naftiridina como moduladores da proteína quinaseInfo
- Publication number
- BRPI0809913A2 BRPI0809913A2 BRPI0809913-8A2A BRPI0809913A BRPI0809913A2 BR PI0809913 A2 BRPI0809913 A2 BR PI0809913A2 BR PI0809913 A BRPI0809913 A BR PI0809913A BR PI0809913 A2 BRPI0809913 A2 BR PI0809913A2
- Authority
- BR
- Brazil
- Prior art keywords
- naphthridine
- derivatives
- protein kinase
- kinase modulators
- modulators
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91046907P | 2007-04-06 | 2007-04-06 | |
| PCT/EP2008/054104 WO2008122614A1 (en) | 2007-04-06 | 2008-04-04 | 2, 6-naphthyridine derivatives as protein kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0809913A2 true BRPI0809913A2 (pt) | 2014-10-07 |
Family
ID=39649350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809913-8A2A BRPI0809913A2 (pt) | 2007-04-06 | 2008-04-04 | Derivados de 2,6-naftiridina como moduladores da proteína quinase |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100130469A1 (pt) |
| EP (1) | EP2144908A1 (pt) |
| JP (1) | JP2010523529A (pt) |
| KR (1) | KR20100016253A (pt) |
| CN (1) | CN101679424A (pt) |
| AU (1) | AU2008235455A1 (pt) |
| BR (1) | BRPI0809913A2 (pt) |
| CA (1) | CA2682339A1 (pt) |
| EA (1) | EA200901348A1 (pt) |
| MX (1) | MX2009010696A (pt) |
| WO (1) | WO2008122614A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE502940T1 (de) * | 2007-04-06 | 2011-04-15 | Novartis Ag | Ä2,6-ünaphthyridine als proteinkinasehemmer |
| MX374758B (es) | 2013-12-13 | 2025-03-06 | Hoffmann La Roche | Inhibidores de tirosina cinasa de bruton. |
| TW202237569A (zh) | 2014-12-24 | 2022-10-01 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| EA032430B1 (ru) | 2014-12-24 | 2019-05-31 | Джилид Сайэнс, Инк. | Конденсированные пиримидины для лечения вич |
| JOP20190257A1 (ar) | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
| GB201915831D0 (en) * | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
| GB201915829D0 (en) * | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017500A (en) * | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| WO2002090360A1 (en) * | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US7449477B2 (en) * | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
| US7880000B2 (en) * | 2004-05-07 | 2011-02-01 | Amgen Inc. | Protein kinase modulators and method of use |
-
2008
- 2008-04-04 JP JP2010501525A patent/JP2010523529A/ja active Pending
- 2008-04-04 KR KR1020097023140A patent/KR20100016253A/ko not_active Withdrawn
- 2008-04-04 EA EA200901348A patent/EA200901348A1/ru unknown
- 2008-04-04 WO PCT/EP2008/054104 patent/WO2008122614A1/en not_active Ceased
- 2008-04-04 CN CN200880018877A patent/CN101679424A/zh active Pending
- 2008-04-04 AU AU2008235455A patent/AU2008235455A1/en not_active Abandoned
- 2008-04-04 CA CA002682339A patent/CA2682339A1/en not_active Abandoned
- 2008-04-04 BR BRPI0809913-8A2A patent/BRPI0809913A2/pt not_active Application Discontinuation
- 2008-04-04 MX MX2009010696A patent/MX2009010696A/es not_active Application Discontinuation
- 2008-04-04 EP EP08735844A patent/EP2144908A1/en not_active Withdrawn
- 2008-04-04 US US12/594,724 patent/US20100130469A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100016253A (ko) | 2010-02-12 |
| CA2682339A1 (en) | 2008-10-16 |
| WO2008122614A1 (en) | 2008-10-16 |
| JP2010523529A (ja) | 2010-07-15 |
| US20100130469A1 (en) | 2010-05-27 |
| MX2009010696A (es) | 2009-10-20 |
| AU2008235455A1 (en) | 2008-10-16 |
| EP2144908A1 (en) | 2010-01-20 |
| CN101679424A (zh) | 2010-03-24 |
| EA200901348A1 (ru) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
| ATE555107T1 (de) | 2-aza-bicyclo-ä2,2,1-üheptan-derivate | |
| BRPI0717320A2 (pt) | Triazóis bicíclicos como moduladores de proteína cinase | |
| BRPI0813707A2 (pt) | Derivados de pirimidinil-piridazinona | |
| BRPI0820112A2 (pt) | Derivados de isoxazol-piridina | |
| BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
| BRPI0714291A2 (pt) | Derivados de [4,5']bipirimidinil-6-4'-diamina como inibidores de proteína cinase | |
| BRPI0820113A2 (pt) | Derivados de isoxazolo-piridazina | |
| BRPI0817562A2 (pt) | derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis | |
| BRPI0716477A2 (pt) | Derivados heteroarila como inibidores de quinase protéica | |
| BRPI0907563A2 (pt) | Derivados de 4,5-di-hidro-xazol-2-il amina | |
| BRPI0812155A2 (pt) | derivados de espiroindolinona | |
| DE602008005634D1 (de) | 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate | |
| BRPI0817935A2 (pt) | Derivados de biarila | |
| BRPI0812518A2 (pt) | Derivados de indazolamida | |
| BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
| BRPI0820649A2 (pt) | Derivados de isoxazalo-pirazina | |
| EP2344471A4 (en) | 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE | |
| BRPI0919898A2 (pt) | 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3 | |
| CU23870B1 (es) | Derivados de ciclopropilamida como moduladores h3 | |
| BRPI0822058A2 (pt) | Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7 | |
| BRPI0917446A2 (pt) | derivados de acilaminobenzamida. | |
| FR2930460B1 (fr) | Distributeur de fragrance. | |
| BRPI0815059A2 (pt) | Derivado de 1,3-di-hidroisoindol | |
| BRPI0806538A2 (pt) | Derivados de glicinamida de espiropiperidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |